A Study of HNC664 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics
A Randomized, Double-blind, Placebo-controlled, Sequential Parallel Group, Single Ascending Doses (SAD) Study Following Oral Administration in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of HNC664
Sponsor: Guangzhou Henovcom Bioscience Co. Ltd.
Listed as NCT04504448, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by Guangzhou Henovcom Bioscience Co. Ltd., it has been updated 7 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
May 2022 — Sep 2022 [monthly]
Recruiting PHASE1
-
Jun 2021 — May 2022 [monthly]
Recruiting PHASE1
▶ Show 2 earlier versions
-
Jan 2021 — Jun 2021 [monthly]
Recruiting PHASE1
-
Sep 2020 — Jan 2021 [monthly]
Recruiting PHASE1
First recorded
Aug 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Guangzhou Henovcom Bioscience Co. Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .